Lung, Phase II
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
Volunteers
Health Professionals
What is the purpose of this trial?
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan, PA
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Benjamin Y. Lu, MD, PhD
- Clarice Grens, APRN
- Elizabeth Gaa, APRN
- Emily Duffield, APRN
- F. Perry Wilson, MD, MSCE
- James Laird, MD
- James Newman, MD
- John Glendening, PA
- Marianne Davies, NP, DNP, MSN, APRN, BSN
- Michael Cohenuram, MD
- Michael Grant, MD
- Roy S. Herbst, MD, PhD
- Sarah Carlson, PA
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- Sharynn Hall, MD, PhD
- Stacey LaRosa, APRN
- Su Hsien Lim, MD
- Victor Chang, MD
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Last Updated05/04/2026
- Study IRB#2000041427